Compositions and methods to combat multidrug-resistant and persistent t-cell-mediated, oncological and infectious diseases

A method for treating a condition, said method comprising the steps of:

• selecting a patient for treatment who has the condition;
• administering to the patient at least one active pharmaceutical ingredient (API);
• and
• administering to the patient at least one metal complex represented by formula (I):
• including hydrates, solvates, pharmaceutically acceptable salts and prodrugs thereof, wherein:
• M is selected from the group consisting of manganese, molybdenum, rhenium, iron, ruthenium, osmium, cobalt, rhodium, iridium, nickel, platinum, and copper;
• X is selected from the group consisting of Cl−, PF6−, Br−, BF4−, ClO4−, CF3SO3−, and SO4−2.
• n=0, 1, 2, 3, 4, or 5;
• y=1, 2, or 3;
• z=0, 1, or 2;
• Lig at each occurrence is independently selected from the group consisting of
• R1 is selected from the group consisting of
• u is an integer of 1 to 20;
• R2a, R2b, R2c, R2d, R2e, and R2f at each occurrence are each independently selected from the group consisting of hydrogen, C1-6 optionally substituted alkyl, C1-6 optionally substituted branched alkyl, C3-7 optionally substituted cycloalkyl, C1-6 optionally substituted haloalkyl, C1-6 optionally substituted alkoxy, CO2R5, CONR62, NR72, sulfate, sulfonate, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, and optionally substituted heterocycle;
• R3a, R3b, R3c, R3d, R3e, R3f, R3g, R3h R3i, R3j, R3k, R3l, and R3m at each occurrence are each independently selected from the group consisting of hydrogen, C1-6 optionally substituted alkyl, C1-6 optionally substituted branched alkyl, C1-6 optionally substituted haloalkyl, C1-6 optionally substituted alkoxy, and CO2R8;
• R4a, R4b, and R4c at each occurrence are each independently selected from the group consisting of hydrogen, C1-6 optionally substituted alkyl, C1-6 optionally substituted C1-6 optionally substituted alkoxy, CO2R5, CONR62, NR72, sulfate, sulfonate, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, and optionally substituted heterocycle;
• R4a and R4bat each occurrence on a thiophene ring are taken together with the atom to which they are bound to form an optionally substituted ring having from 6 ring atoms containing 2 oxygen atoms;
• R5 at each occurrence is independently selected from the group consisting of hydrogen and optionally substituted alkyl;
• R6 at each occurrence is independently selected from the group consisting of hydrogen and optionally substituted alkyl;
• R7 at each occurrence is independently selected from the group consisting of hydrogen and optionally substituted alkyl;
• and
• R8 at each occurrence is independently selected from the group consisting of hydrogen and optionally substituted alkyl,
• wherein:
• the administering to the patient of the at least one metal complex is conducted prior to, during and/or after the administering to the patient of the at least one API;
• and
• the at least one API has a structure not represented by Formula (I).